LGD-4033
Pharmacology detail: animal ratings
These ratios are not measured human benefit or safety rankings.
This profile covers LGD-4033. Compare the ingredient, formulation and evidence with compounds you already recognize, then read the risks.
Technical catalog description
LGD-4033 (Ligandrol) is the mass-oriented mainstream SARM. It is used for lean size, fullness, strength, and scale movement without estrogen-driven water retention.
It is stronger than Ostarine and usually less edgy than RAD-140, but it is still suppressive and can affect lipids. It should be treated as a research drug with real recovery implications, not as a harmless supplement.
Read next
Mechanism details
LGD-4033, or Ligandrol, is the mass-oriented mainstream SARM. Compared with Ostarine, it feels more productive. Compared with RAD-140, it is usually less edgy and less dry. Its role is lean size, fullness, strength, and scale movement without estrogen-driven water retention.
LGD is oral lean-mass support with real suppression. It binds the androgen receptor strongly enough that users often see bodyweight and strength move, but it does not aromatize, does not provide estradiol, and does not function as a testosterone base. The fuller look usually comes from muscle glycogen, training output, and lean-mass accrual rather than the watery bloat associated with Dianabol.
LGD’s reputation as a beginner SARM creates confusion. It may be easier to tolerate than many steroids, but it is still a suppressive research chemical with lipid effects and major sourcing noise.
Natural suppression with reduced fertility and testicular output
Suppression, worsened lipids, and an evidence base that is much thinner than users assume
CBC / hematocrit
blood pressure
lipid panel
Uncontrolled hypertension or untreated cardiovascular disease
Pre-existing severe infertility concerns unless that risk is accepted and managed
LGD is chosen when users want more visible progress than Ostarine without the harsher feel of RAD-140 or S-23. It fits lean bulk and recomp phases where a modest but noticeable size increase is the goal.
Unverified community-use description: Users describe fuller sessions, strength changes, and a gradual increase in bodyweight. These accounts do not establish a daily administration schedule.
LGD is not usually a day-one fireworks compound. The early signal is fuller training and mild scale movement. By weeks 3-5, strength, bodyweight, and muscle fullness usually make the effect clearer.
A reported half-life does not establish that once-daily administration is sufficient. No administration frequency is validated in this catalog.
The main mistake is expecting a steroid cycle while planning recovery like a supplement run. LGD can suppress testosterone enough to affect libido, mood, training drive, and recovery, especially at higher doses or longer durations.
Another mistake is using it without a testosterone or SERM strategy and then confusing low-estrogen symptoms for LGD side effects. A non-aromatizing SARM can lower endogenous testosterone without replacing estradiol support.
Compared with Ostarine, LGD is stronger for size and strength and usually more suppressive.
Compared with RAD-140, LGD is often fuller and less stimulating. RAD is drier, sharper, and more strength-forward.
Compared with Dianabol, LGD is much less dramatic and much drier. Dianabol is faster and wetter; LGD is slower and cleaner but not comparable for mass output.